Related Experiment Videos
Quantitative RNA testing for diagnosis of HIV-infected infants
Steven Nesheim1, Paul Palumbo, Kevin Sullivan
1Emory University School of Medicine, Department of Pediatrics, Infectious Diseases, Epidemiology and Immunology, 69 Butler Street SE, Atlanta, GA 30335, USA. steve_nesheim@oz.ped.emory.edu
Insights
Quantitative HIV RNA testing aids early diagnosis in infants. While highly specific, sensitivity improves after the first week, making it a valuable confirmatory test for HIV-exposed infants.
Area of Science:
- Virology
- Pediatric Infectious Diseases
- Diagnostic Microbiology
Background:
- Early diagnosis of Human Immunodeficiency Virus (HIV) infection in infants is critical for timely treatment and improved outcomes.
- Quantitative HIV RNA testing offers a potential method for early infant diagnosis, but its performance characteristics require thorough evaluation.
- The impact of maternal and infant antiretroviral therapy, specifically zidovudine (ZDV), on RNA test accuracy needs to be understood.
Purpose of the Study:
- To evaluate the sensitivity and specificity of quantitative HIV RNA testing for diagnosing HIV infection in infants younger than six months.
- To assess the influence of maternal and infant zidovudine (ZDV) treatment on the diagnostic accuracy of quantitative HIV RNA tests.
- To compare the utility of quantitative HIV RNA testing with DNA testing in this infant cohort.
Main Methods:
- Quantitative HIV RNA testing was performed on 156 HIV-exposed, non-breast-fed infants under six months of age.
- Infants were categorized as infected (n=54) or uninfected (n=102).
- Sensitivity and specificity were calculated across different age intervals, and paired DNA and RNA analyses were conducted.
Main Results:
- Sensitivity of HIV RNA testing was low in the first week (29%) but increased significantly to over 90% after 29 days of age.
- Specificity was high (100% initially), with a slight decrease to 93% between 29 and 60 days.
- Neither sensitivity nor specificity was significantly impacted by maternal or infant ZDV treatment, despite lower viral loads in infants receiving prophylaxis.
Conclusions:
- Quantitative HIV RNA testing is a viable diagnostic tool for HIV-exposed infants, particularly after the first week of life.
- The test demonstrates high specificity, but clinicians should be aware of potential false positives, especially in the 29-60 day window.
- Quantitative RNA testing may serve as an effective confirmatory test when used alongside other diagnostic methods for infant HIV diagnosis.
Abstract:
Quantitative HIV RNA testing was used for diagnosis in 156 HIV-exposed non-breast-fed infants at less than 6 months of age (54 infected, 102 uninfected) enrolled in the Perinatal AIDS Collaborative Transmission Study. Sensitivity was 29% in the first week, 79% at 8 to 28 days of age, and >90% at 29 days of age and thereafter; specificity was 100% in all periods, except at 29 to 60 days of age, when specificity was 93%. Neither sensitivity nor specificity was significantly affected by maternal or infant zidovudine (ZDV) treatment, even though infant viral loads were lower during the first 6 weeks in infants who received perinatal ZDV prophylaxis ( p=.005). Paired analysis of DNA and RNA measurements revealed no advantage for either test. Quantitative RNA testing can be used for diagnosis in HIV-exposed infants, recognizing the chance for a false-positive test result. It may be most useful as a confirmatory test in infants with another positive diagnostic test result.